Skip to main content

Market Access Monitor

Service of monitoring key reimbursement and HTA developments for medical devices, in-vitro diagnostic tests, and digital technologies in Europe and globally

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Business Venturing in Regulated Markets-Taxonomy and Archetypes of Digital Health Business Models in the European Union: Mixed Methods Descriptive and Exploratory Study

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. 

In a recent publication, Weimar et al. developed a taxonomy and identified six archetypes of business models used by digital health technologies (DHTs) in the European Union. Drawing from 169 real-world DHT cases and 13 expert interviews, the study categorized models as: (1) administration and communication supporter, (2) insurer-to-consumer digital therapeutics and care, (3) diagnostic and treatment enabler, (4) professional monitoring platforms, (5) clinical research and solution accelerators, and (6) direct-to-consumer wellness and lifestyle.

The authors identified three key innovation drivers in the DHT commercialization landscape: the direct targeting of patients and private individuals, the use of artificial intelligence as an enabler, and the development of DHT-specific reimbursement pathways.

Access the full-text article here.